Skip to main content
Log in

Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy

  • MINI REVIEW
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

In cancer chemotherapy with ifosfamide the occurrence of a drug-related encephalopathy represents a severe adverse-effect of unknown origin. We found that the underlying mechanism resides in the mitochondrial toxicity of ifosfamide metabolites. The electron accepting drug methylene blue can substitute for the demonstrated flavoprotein deficiency and its administration leads to resolution of the encephalopathy in patients. The prophylactic administration of methylene blue is equally effective via another principal mechanism, namely oxidation of the excessive quantity of NADH formed during ifosfamide metabolism. The inhibition by methylene blue of multiple amine oxidase activities also prevents formation of the neurotoxic chloroacetaldehyde from ifosfamide-derived chloroethyl amine. Thus, methylene blue exhibits several synergistic modes of actions which enable the dose-limiting neurotoxicity of alkylating chemotherapy with ifosfamide in cancer patients to be overcome

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Additional information

Received: 9 October 1995/Accepted in revised form: 30 January 1996

Rights and permissions

Reprints and permissions

About this article

Cite this article

Küpfer, A., Aeschlimann, C. & Cerny, T. Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy. E J Clin Pharmacol 50, 249–252 (1996). https://doi.org/10.1007/s002280050102

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s002280050102

Navigation